July 18 (Reuters) - Cynapsus Therapeutics Inc
* Top-Line CTH-300 results expected in late Q3 or early Q4
* New drug application for CTH-300 and CTH-301 with FDA expected to be submitted in first half of 2017.
* Cynapsus Therapeutics announces positive phase 3 dose titration phase results with APL-130277 for the treatment of off episodes in patients with Parkinson’s disease
* APL-130277 was well tolerated Source text for Eikon: Further company coverage: